UMN's cell cultured H5N1 vaccine moves forward
This article was originally published in Scrip
Executive Summary
The Japanese bioventure UMN Pharma has begun a Phase II development programme for UMN-0501, its novel recombinant human vaccine for the H5N1 form of influenza.